• Company
• Ultomiris gets expanded indication for neuromyelitis optica
• by Hwang, Byung-woo Jul 17, 2024 05:50am

• Policy
• Ilaris, Orkedia, Latuda will likely be reimbursed next month
• by Lee, Tak-Sun Jul 17, 2024 05:50am

• Policy
• AbbVie renews RSA for leukemia drug 'Venclexta'
• by Lee, Tak-Sun Jul 17, 2024 05:50am

• Company
• Will Eylea K-biosimilar overcome evergreening in the U.S.?
• by Hwang, Byung-woo Jul 16, 2024 05:48am

• Policy
• Temp reimb extension for antivirals including Tamiflu ends
• by Lee, Tak-Sun Jul 16, 2024 05:46am

• Opinion
• [Desk’s View] Respect Korea's generic drug industry
• by Lee, Tak-Sun Jul 16, 2024 05:46am

• Policy
• ‘Exclude GER and CAN or cut price by 50% less'
• by Lee, Tak-Sun Jul 15, 2024 05:48am

• Company
• Bladder cancer drug Balversa lands in KOR 1.5yr after apvl
• by Eo, Yun-Ho Jul 15, 2024 05:47am

• Company
• Severe asthma drug 'Fasenra' lands in general hospitals
• by Eo, Yun-Ho Jul 15, 2024 05:47am

• Company
• K-Bios make progress in new rare lung cancer drug dev
• by Son, Hyung-Min Jul 15, 2024 05:47am